Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Turku University Hospital
• Treatments: Edotreotide; Octreotide; Somatostatin

Criteria

Inclusion Criteria:

• Age: 18 to 70 years old

• Language spoken: Finnish or Swedish

• Performance status: Karnofsky score 70 or better or WHO performance status 2 or better

• Supratentorial malignant glioma based on MRI imaging

• Supratentorial recurrent glioma based on MRI and/or [11C]methionine PET imaging

• Patients must be able to understand the meaning of the study and sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff

Exclusion Criteria:

• Any medical or psychiatric condition that compromises the subject´s ability to participate in the study

• Any other significant disease including liver or renal disease

• Pregnant or lactating women